Novo Nordisk (A dime), reported being criticized by England's Prescription Medicines Practice Organization Code of Practice, or PMCPA, for mishandling certain payments to patients and healthcare teams.

The group is a self-regulatory body that governs the association of the British pharmaceutical industry